A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension

NCT05523323 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

112

Enrollment

INDUSTRY

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: Lenvatinib
BIOLOGICAL: Pembrolizumab
DRUG: Placebo

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]